CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer

Project Number PC0206-000
Brand Name Rozlytrek
Generic Name Entrectinib
Strength 100 mg and 200 mg
Tumour Type Lung
Indication ROS1-positive Non-Small Cell Lung Cancer
Funding Request For the first-line treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer
Review Status Complete
Pre Noc Submission Yes
NOC Date May 5, 2020
Manufacturer Hoffmann-La Roche Ltd.
Sponsor Hoffmann-La Roche Ltd.
Submission Date January 8, 2020
Submission Deemed Complete January 22, 2020
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ January 22, 2020
Check-point meeting March 25, 2020
pERC Meeting December 17, 2020
Initial Recommendation Issued January 8, 2021
Feedback Deadline ‡ January 22, 2021
pERC Reconsideration Meeting (target date)
Final Recommendation Issued January 27, 2021
Notification to Implement Issued February 11, 2021
Therapeutic Area ROS1-positive NSCLC
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.